Signaling pathways in cancer: therapeutic targets, combinatorial treatments, and new developments
Molecular alterations in cancer genes and associated signaling pathways are used to inform
new treatments for precision medicine in cancer. Small molecule inhibitors and monoclonal …
new treatments for precision medicine in cancer. Small molecule inhibitors and monoclonal …
Resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer
ER Scheidemann, AN Shajahan-Haq - International Journal of Molecular …, 2021 - mdpi.com
Estrogen receptor-positive (ER+) breast cancer is the most common form of breast cancer.
Antiestrogens were the first therapy aimed at treating this subtype, but resistance to these …
Antiestrogens were the first therapy aimed at treating this subtype, but resistance to these …
A deep learning model of tumor cell architecture elucidates response and resistance to CDK4/6 inhibitors
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have revolutionized breast cancer
therapy. However,< 50% of patients have an objective response, and nearly all patients …
therapy. However,< 50% of patients have an objective response, and nearly all patients …
[HTML][HTML] Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor
K Freeman-Cook, RL Hoffman, N Miller, J Almaden… - Cancer cell, 2021 - cell.com
Summary The CDK4/6 inhibitor, palbociclib (PAL), significantly improves progression-free
survival in HR+/HER2− breast cancer when combined with anti-hormonals. We sought to …
survival in HR+/HER2− breast cancer when combined with anti-hormonals. We sought to …
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
AJ Al-Qasem, CL Alves, S Ehmsen… - Npj Precision …, 2022 - nature.com
Resistance to aromatase inhibitor (AI) treatment and combined CDK4/6 inhibitor (CDK4/6i)
and endocrine therapy (ET) are crucial clinical challenges in treating estrogen receptor …
and endocrine therapy (ET) are crucial clinical challenges in treating estrogen receptor …
Seize the engine: Emerging cell cycle targets in breast cancer
J Fuentes‐Antrás, PL Bedard… - Clinical and …, 2024 - Wiley Online Library
Breast cancer arises from a series of molecular alterations that disrupt cell cycle
checkpoints, leading to aberrant cell proliferation and genomic instability. Targeted …
checkpoints, leading to aberrant cell proliferation and genomic instability. Targeted …
[HTML][HTML] EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer
S Belli, D Esposito, CM Ascione, F Messina… - Cancer letters, 2024 - Elsevier
In patients with ER+ metastatic breast cancer (mBC), the first-line treatment involves the
combination of endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i). However, a …
combination of endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i). However, a …
Functional activation of the AKT-mTOR signalling axis in a real-world metastatic breast cancer cohort
Background Mutations of the PIK3CA/AKT/mTOR axis are common events in metastatic
breast cancers (MBCs). This study was designed to evaluate the extent to which genetic …
breast cancers (MBCs). This study was designed to evaluate the extent to which genetic …
[HTML][HTML] CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer: translational research, clinical trials, and future directions
JS Lee, H Hackbart, X Cui, Y Yuan - International Journal of Molecular …, 2023 - mdpi.com
The emergence of CDK4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, has
revolutionized the treatment landscape for hormone receptor-positive breast cancer. These …
revolutionized the treatment landscape for hormone receptor-positive breast cancer. These …